Margin operasi Pacific Biosciences (PACB)

Simbol lan logo merek Pacific Biosciences (PACB)

The actual operating margin of Pacific Biosciences (PACB) demonstrates business efficiency, where -98.10 reflects the baseline level of the metric. Pacific Biosciences (PACB) minimizes plastic waste and chemicals as part of its ESG initiatives. The issuer's stability remains high, although government grants may influence equipment procurement. The company is currently actively deploying Revio systems to reduce genome sequencing costs and optimize biochemistry.

PACB: Rentabilitas dodolan operasi PacBio 04.07.2022 - 19.11.2026

Rincian analitis perusahaan Pacific Biosciences

- rega saham lan konsensus proyeksi valuasi:
Analisis fundamental perusahaan:PACB, PacBio Corp
Produk dadi PacBio Corp

Operating margin measures the share of profit from core operations in total revenue before financial expenses and taxes. For Pacific Biosciences (PACB), this calculation reflects the scaling efficiency of Revio systems and the optimization of biochemistry costs. By analyzing the operating profit margin on GURU.Markets, an investor can see the real-time profitability dynamics of the R&D cycle. Growth in this metric confirms a reduction in sequencing costs, signaling the business's transition toward sustainable operational efficiency.

Analisis pesaing

Margin dodolan operasi TEM|QGEN - Tingkat bathi adhedhasar bathi operasi|Margin operasi IONS|RGEN - Rentabilitas dodolan operasi|Rentabilitas operasi Avidity RNA|Margin operasi CRISPR Therapeutics Corp CRSP|GeneDx Corp - Margin operasi|Ultragenyx Pharma (RARE) - Margin dodolan operasi|beamtx.com (BEAM) - Rentabilitas operasi|SRPT: Rasio bathi operasi|Margin dodolan operasi TWST|TXG - Tingkat bathi adhedhasar bathi operasi|Margin operasi NTLA|Rentabilitas kegiatan operasi Stoke Therapeutics|Rentabilitas operasi BioLife Solutions BLFS|Wave Life Sciences (WVE) - Rentabilitas dodolan operasi|Maze Therapeutics, Inc. - Margin operasi|Rentabilitas kegiatan operasi Sionna Therapeutics, Inc. SION|Prime Medicine Bio (PRME) - Rentabilitas operasi|TSHA: Rasio bathi operasi|Rentabilitas operasi uniQure Pharma|MGTX - Tingkat bathi adhedhasar bathi operasi|Margin operasi RGNX|Rentabilitas operasi SLDB (Solid Biosciences)|Ocugen Corp - Margin dodolan operasi|Rasio bathi operasi BNTC (Benitec)|Design Corp - Margin operasi|Rocket Pharmaceuticals - Rasio bathi operasi|Rentabilitas dodolan miturut bathi operasi 4D Molecular Therapeutics, Inc.|Rentabilitas dodolan operasi Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Margin operasi|Rentabilitas dodolan operasi Editas EDIT|Margin operasi SLN|ProQR Therapeutics - Rentabilitas dodolan miturut bathi operasi|Margin operasi CDXS (Codexis, Inc.)|SGMO: Rentabilitas dodolan miturut bathi operasi|Nautilus Biotechnology - Margin operasi|Tingkat bathi operasi MGX (Metagenomi, Inc)|DTIL: Margin operasi|GBIO: Rasio bathi operasi|Rentabilitas operasi Boundless Bio Inc.|Margin dodolan operasi Exicure (XCUR)|Margin operasi IMNN|PHIO (Phio Pharmaceuticals Corp.) - Tingkat bathi operasi|Mustang Bio, Inc. - Margin dodolan operasi|RNAZ - Margin dodolan operasi|BNGO: Margin dodolan operasi|APDN (Applied DNA Sciences Inc) - Rentabilitas dodolan miturut bathi operasi|BLUE (Bluebird Bio) - Margin dodolan operasi|ImmunoPrecise Antibodies Ltd - Tingkat bathi operasi|OMGA (Omega Therapeutics Inc) - Margin operasi|Rentabilitas operasi OMIC|Rentabilitas operasi Regulus Therapeutics Inc. (RGLS)|Margin dodolan operasi Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Margin dodolan operasi|Tingkat bathi operasi TCON|UBX - Rentabilitas operasi